Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase 2 ...
If you grew up in the ’60s or love that era’s style, you might recognize some familiar tableware patterns that were in nearly ...